ARCT Arcturus Therapeutics
- 17.940
- +0.870+5.10%
- 18.000
- +0.060+0.33%
Arcturus Therapeutics News
Analysts Offer Insights on Healthcare Companies: Arcturus Therapeutics (ARCT) and Madrigal Pharmaceuticals (MDGL)
H.C. Wainwright Maintains Arcturus Therapeutics(ARCT.US) With Buy Rating, Maintains Target Price $63
Arcturus Therapeutics Price Target Maintained With a $63.00/Share by HC Wainwright & Co.
Arcturus Therapeutics Analyst Ratings
CCORF Maintains Arcturus Therapeutics(ARCT.US) With Buy Rating, Maintains Target Price $74
H.C. Wainwright Maintains Arcturus Therapeutics(ARCT.US) With Buy Rating, Maintains Target Price $63
Arcturus Therapeutics: Strong Buy Rating Backed by Promising Kostaive Sales and Promising Pipeline Developments
Positive Outlook for Arcturus Therapeutics' Vaccine Production and Distribution Spurs Buy Rating
H.C. Wainwright Maintains Arcturus Therapeutics(ARCT.US) With Buy Rating, Maintains Target Price $63
Arcturus Therapeutics Price Target Maintained With a $63.00/Share by HC Wainwright & Co.
Wells Fargo Maintains Arcturus Therapeutics(ARCT.US) With Buy Rating, Maintains Target Price $58
CCORF Maintains Arcturus Therapeutics(ARCT.US) With Buy Rating, Maintains Target Price $72
CCORF Maintains Arcturus Therapeutics(ARCT.US) With Buy Rating, Maintains Target Price $72
Leerink Partners Maintains Arcturus Therapeutics(ARCT.US) With Buy Rating
Arcturus Therapeutics Analyst Ratings
William Blair Maintains Arcturus Therapeutics(ARCT.US) With Buy Rating
CCORF Maintains Arcturus Therapeutics(ARCT.US) With Buy Rating, Maintains Target Price $72
Buy Rating Affirmed: Arcturus Therapeutics' Promising Cystic Fibrosis Program Progress
CCORF Maintains Arcturus Therapeutics(ARCT.US) With Buy Rating, Maintains Target Price $72
Arcturus Therapeutics Analyst Ratings
No Data